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Abstract: Along with the growing epidemic of obesity, the risk of atherosclerosis, cardiovascular 
disease morbidity, and mortality are increasing markedly. Several risk factors for cardiovascular 
disease, such as visceral obesity, glucose intolerance, arterial hypertension, and dyslipidemia 
commonly cluster together as a condition currently known as metabolic syndrome. Thus far, 
insulin resistance, and endothelial dysfunction are the primary events of the metabolic syndrome. 
Several groups have recommended clinical criteria for the diagnosis of metabolic syndrome in 
adults. Nonetheless, in what concerns children and adolescents, there are no uniﬁ  ed deﬁ  nitions, 
and modiﬁ  ed adult criteria have been suggested by many authors, despite major problems. Some 
pediatric disease states are at risk for premature cardiovascular disease, with clinical coronary 
events occurring very early in adult life. Survivors of speciﬁ  c pediatric cancer groups, particularly 
acute lymphocytic leukemia, central nervous system tumors, sarcomas, lymphomas, testicular 
cancer, and following bone marrow transplantation, may develop metabolic syndrome traits 
due to: hormonal deﬁ  ciencies (growth hormone deﬁ  ciency, thyroid dysfunction, and gonadal 
failure), drug or radiotherapy damage, endothelial impairment, physical inactivity, adipose 
tissue dysfunction, and/or drug-induced magnesium deﬁ  ciency. In conclusion, some primary 
and secondary prevention remarks are proposed in order to reduce premature cardiovascular 
disease risk in this particular group of patients.
Keywords: metabolic syndrome X, cardiovascular diseases, insulin resistance, obesity, growth 
hormone/deﬁ  ciency, endothelium, vascular/physiopathology
Metabolic syndrome and cardiovascular disease
Along with the growing epidemic of obesity and chronic diseases, the risk of atheroscle-
rosis, as well as cardiovascular disease (CVD) morbidity and mortality, are increasing 
markedly (Waychenberg 2000). Reaven (1988) noted that several risk factors for CVD 
commonly cluster together, and he recognized them as a disease, named syndrome X, 
currently known as metabolic syndrome (MS). Insulin resistance (IR) is considered the 
primary cause of associated cardiovascular risk factors and the probable mechanism 
linking all the MS comprising features, such as visceral obesity, glucose intolerance, 
type 2 diabetes mellitus (T2DM), arterial hypertension, atherogenic dyslipidemia, 
proinﬂ  ammatory, and prothrombotic state (Sarti and Gallagher 2006).
Viscerally distributed adipose tissue, rather than subcutaneous fat, plays a major 
role in this process (Waychenberg 2000). Adipose tissue is controlled by several 
signals, including insulin and growth hormone (GH), and has been considered as 
an endocrine organ (Mohamed-Ali et al 1998). Adipocytes secrete inﬂ  ammatory 
mediators and adipokines (comprising leptin and adiponectin), that regulate endothelial 
function, atherogenesis, and energetic balance. Adipokines also activate intracellular 
pathways, regulating the subacute inﬂ  ammatory state associated with obesity, and Vascular Health and Risk Management 2008:4(4) 826
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the development of IR and T2DM (Shoelson et al 2006). 
Endothelial dysfunction (reﬂ  ected principally by microalbu-
minuria) is associated with MS components, and is present 
in patients suffering from atherosclerosis. Overall, it is not 
clear yet whether IR is cause or consequence of endothelial 
dysfunction (Nuver et al 2002). To date, an increased risk of 
CVD death is more pronounced when MS itself is present. 
However, each individual component of MS may also confer 
increased occurrence of CVD. So far, the more components 
of MS that are evident, higher is the cardiovascular mortality 
rate (Hu et al 2004).
Deﬁ  ning metabolic syndrome
Several groups have recommended clinical criteria for the 
diagnosis of MS in adults (Alberti and Zimmet 1998; Balkau 
and Charles 1999; ADA 2000; NCEP–ATP III 2001; Einhorn 
et al 2003; Genuth et al 2003; Grundy et al 2004; IDF 2006). 
Deﬁ  nition data regarding different criteria are summarized 
in Table 1.
In what concerns the pediatric population, there are sev-
eral difﬁ  culties in determining MS features. Some authors 
have proposed modiﬁ  ed adult criteria, taking into account 
child speciﬁ  c cutoff values and percentiles (Cook et al 2003; 
Cruz et al 2004; DeFerranti et al 2004; Weiss et al 2004; 
Jones 2006). Insulin sensitivity, an important diagnostic 
condition for MS, is difﬁ  cult to obtain, especially in pedi-
atric patients. To date, hyperinsulinemic clamp has been 
considered the gold-standard for insulin evaluation, but this 
is a complicated method to be applied in children. Moreover, 
insulin sensitivity changes with age and puberty, while it is 
negatively correlated with visceral obesity. Data for percen-
tiles of waist circumference that are speciﬁ  c to ethnic origin 
are becoming increasingly available (Zimmet et al 2007), 
and have been suggested in MS deﬁ  nition criteria in pediatric 
patients, rather than body mass index (BMI). In addition, BMI 
was converted to standard deviation scores (SDS) or percen-
tiles for comparisons, with the basis of the National Center 
for Health Statistics (NCHS) 2000 international reference. 
Blood pressure percentiles were determined according to the 
National High Blood Pressure Education Program Working 
Group on Hypertension Control in Children and Adolescents 
(1996), while lipid levels were analyzed with the basis of dif-
ferent existing criteria (AAP 1992; Hickman et al 1998). On 
the other hand, the International Diabetes Federation (IDF) 
has recently redeﬁ  ned MS in children and adolescents, and 
has proposed requiring parameters in absolute values, rather 
than age-related percentile cutoffs. Moreover, it has also 
been suggested that MS should not be diagnosed in children 
Table 1 Metabolic syndrome deﬁ  nition in adults according to different criteria (Adapted from Grundy et al 2004)
Risk factors WHO (1998) EGIR (1999) NCEP–ATP III (2001) AACE (2003) IDF (2006)
Requirement T2DM , impaired fast-
ing glucose, IGT or IR 
(HOMA-IR) + 2 of 
the following
Hiyperinsulinemia 
or IR + 2 of the 
following
3 of the following Depends on clinical 
judgment based 
on risk factors as 
following*
Central obesity + 
2 of the following
Blood pressure Antihypertensive drug 
and/or 140/90 mmHg 
with no treatment
140/90 mmHg or 
antihypertensive drug
130/85 mmHg 130/85 mmHg Antihypertensive 
drug or 130/85 
mmHg
Triglycerides 150 mg/dL 180 mg/dL 150 mg/dL 150 mg/dL 150 mg/dL
HDL-cholesterol M: 35 mg/dL F: 
39 mg/dL
40 mg/dL M: 40 mg/dL F: 50 
mg/dL
M: 40 mg/dL F: 
50 mg/dL
M: 40 mg/dL 
F: 50 mg/dL
Central obesity BMI 30 kg/m2 and/or 
M: W/H 0.90 F: W/H 
0.85
M: W 94 cm F: W 
80 cm
M: W 102 cm F: W 
88 cm
BMI 25 kg/m2 M: 
W 102 cm F: W 
88 cm
M: W 94 cm 
F: W 80 cm
Microalbuminuria 20 μg /min -- - -
Glucose/insulin T2DM, impaired fasting 
glucose, IGT or IR 
(HOMA-IR)
Fasting glucose 110 
mg/dL‡
Fasting glucose 110 
mg/dL ‡
Fasting glucose 
110–125 mg/dL‡ or 
IGT
Fasting glucose 
100 mg/dL 
(OGTT recom-
mended) or previ-
ous T2DM
Abbreviations: WHO, World Health Organisation (Alberti and Zimmet 1998); EGIR, European Group for the Study of Insulin Resistance (Balkau and Charles 1999); NCEP–ATP III, 
National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III 2001); AACE,  American College of Endocrinology/American Association of Clinical Endocrinolo-
gist (Einhorn et al 2003); IDF, International Diabetes Federation (2006); T2DM, type 2 diabetes mellitus (fasting glucose 126 mg/dL); IGT, Impaired glucose tolerance†; IR, insulin 
resistance; HOMA-IR, homeostasis model assessment; M, male; F, female; BMI, body mass index; W, waist; H, hip; W/H, waist to hip ratio; OGTT, oral glucose tolerance test.
Notes: *Other risk factors: polycystic ovary syndrome, sedentary lifestyle, advancing age, ethnic groups having high risk for T2DM or cardiovascular disease; †IGT: OGTT post-2 h 
glucose 140 mg/dL and 200 mg/dL; ‡American Diabetes Association (ADA 2000). However, a cutpoint of 100 mg/dL has been recently established, and should be applicable 
for identifying the lower boundary to deﬁ  ne an elevated glucose as one criterion for the metabolic syndrome (Genuth et al 2003).Vascular Health and Risk Management 2008:4(4) 827
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younger than 10 years, even though visceral obesity should 
call for attention (Zimmet et al 2007). See Table 2.
Pediatric patients at high-risk: 
Attention to childhood cancer 
survivors
The prevalence of MS and risk assessment is quite diverse, 
depending on the diagnostic criteria and assortment of popu-
lation, but there is full agreement that it is clearly growing in 
overweight adults and pediatric patients (Grundy et al 2004). 
Notwithstanding, several pediatric conditions predisposing 
to the syndrome, as well MS comprising traits, should be 
identiﬁ  ed earlier in childhood, in order to prevent CVD in 
adult life (Zimmet et al 2007). Typical examples are homo-
zygous hypercholesterolemia, diabetes mellitus, chronic kid-
ney disease, congenital heart disease, heart transplantation, 
Kawasaki disease, chronic inﬂ  ammatory disease, systemic 
lupus erythematosus, rheumatoid arthritis, and cancer treat-
ment during childhood (Kavey et al 2006).
In the last twenty years, along with the better care commit-
ted to children with cancer, the establishment of chemotherapy 
(CT) and the advances in radiotherapy (RT), survival rates 
have greatly improved. Consequently, the number of patients 
that reach adulthood presenting some treatment-related health 
problems or mortality due to CVD is increasing continuously 
(Oefﬁ  nger et al 2001). According to a statement developed 
by the American Heart Association along with the Council 
for Cardiovascular Disease in the Young, based on the study 
of several pediatric states and their risk for CVD, post-cancer 
treatment survivors were classiﬁ  ed as tier III, which means 
increased cardiovascular risk factors, with epidemiological 
evidence for manifest CVD early in adult life, but after 30 
years of age (Kavey et al 2006). Survivors of speciﬁ  c pediatric 
cancer groups, particularly acute lymphocytic leukemia (ALL), 
central nervous system (CNS) tumors, sarcomas, lymphomas, 
disseminated testicular cancer, neuroblastomas, Wilms tumors, 
and following bone marrow transplantation (BMT), are 
recognized to present clinical features of MS, and therefore 
increased risk factors for CVD, such as visceral obesity, IR, 
glucose intolerance, dyslipidemia, arterial hypertension, and 
endothelial dysfunction (Heikens et al 2000; Oefﬁ  nger et al 
2001; Link et al 2004; Nuver et al 2005; Gurney et al 2006; 
Neville et al 2006; Janiszewski et al 2007; Razzouk et al 2007; 
Taskinen et al 2007; Trimis et al 2007; Hoffman et al 2008).
Metabolic syndrome and cancer: 
What comes ﬁ  rst?
Different studies have shown that cancer and several chronic 
diseases may have some risk factors in common, considered 
features of MS, such as obesity, hyperinsulinemia, and IR. 
Table 2 Metabolic syndrome deﬁ  nition in children and adolescents according to different criteria (Adapted from Jones 2006; Zimmet 
et al 2007)
Risk factor Cook et al 2003 Cruz et al 2004 DeFerranti 
et al 2004
Weiss et al 2004 IDF 2007
Requirement 3 out of 5 of the 
following
3 out of 5 of the 
following
3 out of 5 of the 
following
3 out of 5 of the 
following
BMI 90th percentile + 2 
of the following
Age (years) 12–19 8–13 12–19 4–20 10–16
Blood pressure 90th percentile 
or antihypertensive 
drug
90th percentile 90th percentile 95th percentile Systolic blood pressure 
130 mmHg or diastolic 
85 mmHg
Triglycerides 110 mg/dL 90th percentile 100 mg/dL 95th percentile 150 mg/dL
HDL-cholesterol 40 mg/dL 10th percentile M*: 45 mg/dL 
F: 50 mg/dL
5th percentile 40 mg/dL
Central obesity BMI 95th 
percentile W 90th 
percentile
W 90th percentile W 75th per-
centile
BMI 2 SDS W 90th percentile
Glucose/insulin Fasting glucose 
110 mg/dL‡ 
IGT, T2DM or IR 
(HOMA-IR)
IGT Fasting glucose 
110 mg/dL‡
IGT or IR 
(HOMA-IR)
Fasting glucose 100 mg/dL 
(OGTT recommended) or 
T2DM
Abbreviations: IDF, International Diabetes Federation (Zimmet et al 2007); BMI, body mass index; W, waist; IGT, impaired glucose tolerance†; T2DM, type 2 diabetes mellitus; 
IR, insulin resistance; HOMA-IR, homeostasis model assessment; M, male; F, female; SDS, standard deviation score; OGTT, oral glucose tolerance test.
Notes: †IGT: OGTT post-2 h glucose 140 mg/dL and 200 mg/dL; *Males 15–19 yr; ‡American Diabetes Association (ADA 2000). However, a cutpoint of 100 mg/dL 
has been recently established, and should be applicable for identifying the lower boundary to deﬁ  ne an elevated glucose as one criterion for the metabolic syndrome 
(Genuth et al 2003).Vascular Health and Risk Management 2008:4(4) 828
Siviero-Miachon et al
Nonetheless, it remains controversial if such risk factors are 
cause or consequence of chronic diseases, including cancer 
(Hsu et al 2007).
The association between diabetes mellitus and cancer was 
reported more than 100 years ago (Harish et al 2007), and 
population studies have shown increased evidence that MS is 
increasing worldwide, in parallel with an increasing of cancer 
incidence (Zhou et al 2007). Moreover, diabetes and obesity 
have been recognized as risk factors for the development of 
breast, endometrial, colorectal, and pancreatic carcinomas. 
To date, the association between diabetes, obesity, and 
cancer incite speculations about the mechanisms linking IR 
and adiposity, components of MS, and the development of 
certain types of cancer. However, the relation between MS 
(and its consequent biochemical derangements) and cancer 
still remains unexplained (Harish et al 2007).
Carcinogenesis is multifactorial, and depends not only 
on metabolic disturbances, but also on the inherited genetic 
background. Part of the carcinogenic effect could be attributed 
to adiposity, through hyperinsulinism, and additional mecha-
nisms, that may include chronic inﬂ  ammation and oxidative 
stress associated with obesity (Harish et al 2007; Hsu et al 
2007). Insulin itself may also be an important factor linking 
IR to cancer (Hsu et al 2007). Previous statements have shown 
ample evidence suggesting that high levels of insulin (due to   
IR) increase insulin-like growth factor (IGF)-1 bioavailability 
by means of suppression of IGF binding protein 1 and 3 
(IGFBP-1 and 3). IGF-1 has a role in promoting carcinogenesis 
and IGF-1 receptor is crucial for tumor transformation, and 
survival of malignant cells. Moreover, speciﬁ  c polymorphisms 
in certain genes encoding proteins involved in IGF-signaling 
pathway, including IGF-1 itself, are associated with variation in 
cancer risk (Harish et al 2007; Pollak 2007; Zhou et al 2007).
On the other hand, it remains highly controversial if 
carcinogenesis could possibly contribute to the develop-
ment of MS in survivors of various malignancies. This is 
still little understood, but there are several speculations over 
it. The neoplasms may probably cause changes on insulin 
sensitivity, lipid metabolism, inflammatory mediators, 
and adipokines, which may be aggravated by anticancer 
therapies, including CT and RT. Thus far, the best bio-
logical model to study the relationship between cancer and 
the components of MS is cancer cachexia, which affects 
more than a half of cancer patients (Saini et al 2006). Can-
cer cachexia is considered a complex and multifactorial 
metabolic disorder involving features of anorexia, asthenia, 
lipolysis, changes in body composition, systemic inﬂ  am-
mation, IR, and may predispose to long-term metabolic 
disturbances, and decreased lean body mass and muscles, 
that remain insulin resistant, analogous to the state proposed 
by the Barker hypothesis after intrauterine growth retarda-
tion (Barker 1995; Saini et al 2006).
Metabolic syndrome features 
in childhood cancer survivors
Thus far, the mechanisms behind increased cardiovascular 
risk factors in childhood cancer survivors are not clariﬁ  ed 
yet. Notwithstanding, there is a strong possibility that some 
pathways, different from those in non-cancer populations, 
may be activated in childhood cancer survivors, underlying 
mechanisms for weight gain and IR. These include various 
hormones deﬁ  ciencies, changes on insulin sensitivity, lipid 
metabolism, inﬂ  ammatory mediators and adipokines, as well 
as reduced physical activity, which may be altered by vari-
ous cancer therapies. Local treatments, such as surgery and 
RT, may lead to multiple endocrine deﬁ  ciencies and, con-
sequently, to MS comprising features. Systemic treatments, 
like CT, may contribute to MS in several ways: damage of 
endocrine organs or nonhormonal systems, such as magne-
sium metabolism, as well as endothelial, and adipose tissue 
dysfunction (Nuver et al 2002; Kavey et al 2006).
Regarding childhood cancer survivors at risk for MS, and 
consequently considered at risk for premature development 
of CVD, we described the possible mechanisms determin-
ing MS, focusing on speciﬁ  c pediatric cancer groups, in 
which weight gain, endocrine and metabolic disturbances 
are especially prevalent.
Mechanisms of metabolic syndrome 
in childhood cancer survivors
Growth hormone deﬁ  ciency 
and intima-media thickness
Growth hormone (GH) deﬁ  ciency in childhood cancer survi-
vors may be attributed to the tumor itself, depending on the 
location in the hypothalamic-pituitary region, or to an adverse 
effect of treatment, comprising cranial RT, and/or CT. GH 
is implicated not only in growth regulation, but also in 
metabolism. GH deﬁ  ciency frequently induces MS-like dis-
orders, such as hypertriglyceridemia, low HDL-cholesterol, 
coagulopathy, and hypertension. Despite evidence linking 
GH deﬁ  ciency to the components of MS and CVD, the rela-
tionship between the syndrome and GH secretion status has 
not been established yet. Thus far, two important conditions 
related to GH deﬁ  ciency, IR and endothelial dysfunction, 
justify especial considerations (Nuver et al 2002).Vascular Health and Risk Management 2008:4(4) 829
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So far, increased intima-media thickness (IMT), an 
intermediate marker for CVD, has been described in the com-
mon carotid arteries of untreated children and adults with GH 
deﬁ  ciency, and has been inversely correlated with IGF-1 levels 
(Szczepaniska-Kostro et al 2004; Soares et al 2005). In what 
concerns oncologic patients, no differences were recorded in 
artery thickness between ALL survivors regardless of cranial 
RT at dose up to 24 Gy (Oefﬁ  nger et al 2001; Link et al 2004). 
In contrast, an increased IMT in the carotid bulb of childhood 
CNS tumors survivors who received high-dose cranial RT 
(45 Gy) was described by Heikens and colleagues (2000). 
In conclusion, IMT seems to be positively correlated with 
cranial RT dose employed, and negatively correlated with 
IGF-1 levels, which in turn reﬂ  ect GH status.
To date, GH replacement therapy in both oncologic 
and nononcologic GH-deﬁ  cient patients can improve mor-
phological and functional changes predisposing to CVD, 
particularly body composition (Bülow et al 2004; Colao 
et al 2005; Soares et al 2005). Nevertheless, the positive 
effects of GH replacement while on therapy usually do not 
persist after GH is discontinued, and depend on the period 
of replacement. A short-term GH replacement (12 months) 
induces favorable outcome, comprising metabolic parameters 
and body composition, however the beneﬁ  cial effects on 
vascular damage (IMT) are only seen after long-term GH 
therapy (2 years) (Soares et al 2005). Finally, IMT was not 
prospectively evaluated while on GH therapy in the oncologic 
population (Bülow et al 2004).
Thyroid dysfunction
Thyroid dysfunction is an important adverse late-effect of 
cancer therapy, especially after neck RT, as CT alone does 
not possibly impair thyroid function. Several malignancies, 
encompassing tumors of CNS requiring craniospinal RT 
(medulloblastomas), lymphomas or neck tumors requiring 
locally administered RT, as well as following conditioning 
total body irradiation (TBI) before BMT, are at risk for thyroid 
dysfunction (Nuver et al 2002; Gleeson and Shalet 2004).
The hypothyroid state affects the cardiovascular system 
through both an inﬂ  uence on the heart and adverse effects 
on serum lipids, increasing the risk of development of CVD 
(Nuver et al 2002). Nevertheless, subclinical hypothyroid-
ism, a state with elevated thyroid stimulating hormone (TSH) 
concentrations (5.0 mIU/L) and normal levels of thyroxin 
(T4) and triiodothyronine (T3) in asymptomatic subjects, 
commonly presented in long-term survivors of cancer, was 
not associated with increased risk for CVD (Nuver et al 
2002). According to the European Organisation for Research 
and Treatment of Cancer database, in-field RT against 
aggressive non-Hodgkin’s lymphomas, consistently treated 
with doxorubicin-based CT, was related to hypothyroidism, 
but not to CVD (Moser et al 2005).
Gonadal failure
Despite the continuous improvement of cancer treatment pro-
tocols, gonadal failure is a frequent adverse effect in long-term 
cancer survivors, which may result in hormonal production 
impairment (hypogonadism), and in the risk of developing 
MS. It may occur as a consequence of gonadectomy, direct 
damage of RT to gonads, and/or CT-comprising alkylant drugs 
(busulfan, cyclophosphamide and iphosphamide) or platinum 
compounds (carboplatin and cysplatin). So far, estrogens and 
testosterone are known to inﬂ  uence body composition, lipid 
metabolism, vascular tone, and blood pressure (Nuver et al 
2002; Gleeson and Shalet 2004; Rutter and Rose 2007).
In male gonads, oligo or azoospermia may occur after 
low-dose RT or alkylating CT, whereas Leydig cells and 
testosterone production are relatively resistant to damage. On 
the other hand, in females, RT and cytotoxic treatment may 
partially or deﬁ  nitively affect both, reproductive function and 
hormonal production, resulting in premature ovarian failure 
(POF), with amenorrhea or irregular menses (Nuver et al 2002; 
Brydøy et al 2007; Rutter and Rose 2007). According to the 
Childhood Cancer Survivor Study (CCSS), the risk factors to 
POF in females are: older age at tumor diagnosis, Hodgkin’s 
lymphoma, pelvic RT at or above 10 Gy or alkylating agents at 
ages of 13–20 years (Sklar et al 2006). Thus, CT after pubertal 
onset seems to be more destructive to the ovaries compared 
to therapy during childhood (Rutter and Rose 2007). Overall, 
hormone deﬁ  ciency in both sexes, rather than infertility, is 
somehow connected to the risk of developing MS features.
Magnesium deﬁ  ciency
Systemic anticancer therapies can cause derangement of 
nonhormonal systems, leading to metabolic disorders, com-
prising magnesium (Mg+2) levels. To date, Mg+2 levels play 
a role in insulin sensitivity and vascular tone. Generally, 
hypomagnesemia has been implicated in the development 
of metabolic disorders, IR and hypertension, increasing the 
risk of atherosclerosis and CVD (Nuver et al 2002).
Hypomagnesemia is a common effect following cytotoxic 
agent, particularly cysplatin, but its clinical importance needs 
to be better evaluated. Possible symptoms of hypomagne-
semia are undistinguished from symptoms related to the 
underlying disease or from the CT-induced symptoms (Nuver 
et al 2002; Hodgkinson et al 2006). Moreover, after initiation Vascular Health and Risk Management 2008:4(4) 830
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of treatment for ALL, rapid recovery in bone formation, 
which results in the movement of extracellular Mg+2 into 
the skeleton through bone formation, may be an important 
contributor to hypomagnesemia (Guo et al 2004).
Other causes
Vulnerable-child syndrome, lack of adequate physical activ-
ity due to damage to the muscles or nerves following CT or 
RT, altered behavior, energy utilization, and sleep patterns, as 
well as stress, may also contribute to MS comprising features. 
Physical inactivity further increases the risk of CVD, osteo-
porosis, and all-cause mortality. Sleepiness and narcolepsy 
were reported in craniopharyngioma patients, exacerbating 
hypothalamic obesity, and were associated with deﬁ  ciency of 
orexin and melatonin (Rutter and Rose 2007). Exercise may 
suppress inﬂ  ammatory responses and improves insulin sensitiv-
ity, rates of protein synthesis and antioxidant activities (Florin 
et al 2007). Although CT agents may also cause adipose tissue 
derangement, thus far little is known about this statement.
Mild hyperhomocystinemia is a recently recognized 
risk factor in the development of CVD, leading to endothe-
lial dysfunction and development of atherosclerosis. It is 
most commonly secondary to polymorphisms of enzymes 
involved in homocysteine (Hcy) metabolism, aggravated by 
the employment of methotrexate, which induces Hcy spikes 
and endothelial damage (Oefﬁ  nger 2008).
Acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL) is the most common 
childhood malignancy, and it has been considered an 
important model to study the metabolic disorders and their 
relationship to the oncologic disease. Studies from the CCSS 
have reported an increased risk of all-cause mortality, car-
diovascular-related mortality, cerebrovascular accidents, and 
chronic health conditions in long-term survivors of childhood 
ALL (Mertens et al 2001).
The association of obesity and cranial RT is well-
established (Oefﬁ  nger 2008). From the CCSS, ALL survivors 
who have received 20 Gy cranial RT (frequently 24 Gy) were 
at increased risk of overweight/obesity, especially females 
treated at a young age (5 years) (Oefﬁ  nger et al 2003). 
Other studies have also conﬁ  rmed this association of cranial 
RT and obesity (Sklar et al 2000). Excessive weight gain dur-
ing ALL treatment is usually related to steroids effects and 
CNS treatment on appetite regulation, as well as less energy 
expenditure. Nevertheless, these factors do not fully explain 
overweight in this group of patients (Dalton et al 2003). Early 
adiposity rebound (AR) is an additional mechanism that might 
contribute to obesity in survivors of ALL. The AR is the period 
of childhood (typically between 5 and 7 years) when BMI and 
other indexes of adiposity begin to increase after reaching their 
nadir (Reilly et al 2001). Leptin regulation disorder and leptin 
resistance have also been hypothesized to play a role in the 
development of obesity in ALL survivors. Leptin is an impor-
tant adiposity index during and after ALL therapy as it cor-
relates positively with BMI (Argüelles et al 2000; Adan et al 
2001; Siviero-Miachon et al 2007). In addition, leptin receptor 
polymorphism may also inﬂ  uence obesity in female survivors 
of childhood ALL, particularly those exposed to cranial RT 
(Ross et al 2004). On the other hand, most children treated for 
ALL do not receive cranial RT, or RT dose employed may 
vary between 12 and 18 Gy (low-dose). Whether CT only or 
low-dose cranial RT are related to the development of obesity 
is controversial, but this association has been greatly reported 
by various previous statements (Argüelles et al 2000; Reilly 
et al 2001; Dalton et al 2003; Razzouk et al 2007).
Additionally, young adult survivors of childhood ALL are 
also at risk for MS traits, such as visceral adiposity, dyslipid-
emia, IR, and hypertension. While CT predisposes to features 
of MS in ALL survivors, cranial RT increases this predisposi-
tion (Talvensaari et al 1996; Oefﬁ  nger et al 2001; Link et al 
2004; Jarfelt et al 2005; Gurney et al 2006; Janiszewski et al 
2007; Trimis et al 2007). All these statements strongly linked 
the prevalence of MS features to GH deﬁ  ciency and in turn 
to cranial RT, even though obesity, and MS traits (as well as 
GH deﬁ  ciency) have also been described in patients treated 
with CT and corticosteroids only (Kourti el al 2005).
Central nervous system tumors
Obesity and multiple pituitary hormone deﬁ  ciencies are 
common complications after treatment of CNS tumors. To 
date, the major risk factors that predict the development of 
obesity in CNS tumors survivors are, as follows: hypotha-
lamic location, extent of surgery, hypothalamic irradiation 
exceeding 51 Gy, and the presence of hypothalamic-pituitary 
deﬁ  ciencies, particularly GH deﬁ  ciency (Lustig et al 2003; 
Ahmet et al 2006).
Heikens and colleagues (2000) described an altered 
risk proﬁ  le for CVD as elevated systolic blood pressure, 
altered body composition, and a less favorable lipid proﬁ  le 
in long-term survivors of childhood CNS tumors (medul-
loblastoma, astrocitoma, ependymoma, craniopharyngioma 
and nasopharynx carcinoma), who received cranial RT 
exceeding 45 Gy. The altered metabolic proﬁ  le, as well as a 
larger IMT in the carotid artery bulb, were more pronounced 
in a subgroup with GH deﬁ  ciency due to cranial RT, so Vascular Health and Risk Management 2008:4(4) 831
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that these changes may be attributed to GH deﬁ  ciency and 
predate the development of symptomatic atherosclerosis. 
Similarly, the existing statements concerning hyperphagia 
and uncontrolled hypothalamic obesity secondary to cranio-
pharyngioma involve patients treated with either surgery or 
RT, and correlate ﬁ  ndings to GH deﬁ  ciency due to hypo-
thalamic damage. According to Srinivasan and colleagues 
(2004), post-craniopharyngioma surgery in children may 
increase the risk for MS, including IR due to excess weight 
gain and GH deﬁ  ciency. However, other possible contribut-
ing mechanisms include lack of sensitivity to endogenous 
leptin (Roth et al 1998), vagally mediated hyperinsulinemia 
(Lustig et al 2003), autonomic imbalance (Lustig 2003), as 
well as reduced physical activity (Harz et al 2003).
Sarcomas
Recently, an increased prevalence of MS traits, compris-
ing hypertension, hypertriglyceridemia, and male visceral 
abdominal obesity, has been described in pediatric sarcomas 
survivors (predominantly Ewings), treated with multi-agent 
CT, and with or without RT (Hoffman et al 2008). Taking 
into account the NCEP–ATP III criteria (three or more MS 
traits), there were no differences between the prevalence of 
MS comparing the study cohort and general population, but 
young survivors, aged less than 40 years, appear to be more 
affected (Hoffman et al 2008). This statement concurs with 
the one stated by the American Heart Association along 
with the Council for Cardiovascular Disease in the Young, 
suggesting that post-cancer treatment survivors exhibit epi-
demiological evidence for manifest CVD early in adult life, 
and after 30 years of age (Kavey et al 2006). There was no 
association between MS traits and markers of inﬂ  ammation 
and coagulation in pediatric sarcomas survivors. On the 
other hand, testosterone levels declined as the number of 
MS features increased, similarly to the condition described 
to disseminated testicular cancer survivors (Nuver et al 2005; 
Hoffman et al 2008). No association between GH deﬁ  ciency 
and the occurrence of MS traits were observed, although GH 
deﬁ  ciency was seen in survivors with or without cranial RT. 
Physical inactivity due to altered ambulatory function, a con-
sequence of surgical resection and/or RT to thrunk, pelvic and 
lower extremity may also contribute for the development of 
MS in pediatric sarcomas survivors (Hoffman et al 2008).
Other types of cancer
Features of MS have also been described in disseminated tes-
ticular cancer, lymphomas, neuroblastomas, and Wilms tumors 
(Nuver et al 2005; Razzouk et al 2007; Hoffman et al 2008). 
The mechanisms involved are similar to those described in other 
types of cancer. While the association between lymphomas, 
neuroblastomas, Wilms tumors and MS traits are not often 
reported, much attention has been given to the relationship 
between testicular cancer and the features of MS. To date, 
long-term survivors of disseminated testicular cancer treated 
with cisplatin-based CT presented with dyslipidemia, hyperten-
sion, microalbuminuria, overweight, IR, and increased plasma 
levels of endothelial and inﬂ  ammatory marker proteins, which 
might progress to more severe endothelial dysfunction, and 
overt atherosclerosis. Testosterone deﬁ  ciency, rather than other 
dysfunctions, may play a role in the development of MS in this 
particular group of patients (Nuver et al 2002; 2005).
Bone marrow transplantation
Bone marrow transplantation (BMT), including allogeneic 
and autologous transplantation of stem cells from bone 
marrow, peripheral blood, and umbilical cord blood, has 
increased dramatically in recent years. BMT is applied mainly 
to treat poor-prognosis leukemia and solid tumors, but it is also 
effective in curing hematological, immunological, genetic, and 
metabolic nonhematological diseases. As long as the number 
of BMT increases, the number of long-term survivors of BMT 
is steadily increasing, and so endocrine effects usually occur 
as a consequence of pretransplant conditioning regimens. 
The most common endocrine dysfunctions following BMT 
are growth disturbances, thyroid dysfunction, gonadal failure, 
and osteoporosis (Shalitin et al 2006).
Currently, it is becoming clear from a number of studies 
among adult and pediatric recipients of BMT that they are 
also at risk of developing abdominal adiposity, IR and other 
features of MS, such as impaired glucose tolerance, T2DM, 
dyslipidemia, and hypertension. Early unexplained mortal-
ity in adult recipients of BMT has raised concerns regard-
ing accelerated cardiovascular risk in this group of patients 
(Higgins et al 2004; Chatterjee et al 2005; Neville et al 2006; 
Shalitin et al 2006; Baker et al 2007; Taskinen et al 2007). 
The relative risk is inﬂ  uenced by the underlying disease, 
previous treatments (cranial RT or alkylating CT agents), 
post-BMT treatments, older age and advanced pubertal stage 
at BMT, GH deﬁ  ciency, and genetic predisposition (family 
history of dyslipidemia and T2DM) (Shalitin et al 2006). TBI, 
untreated hypogonadism, and abdominal adiposity (a known 
feature of GH deﬁ  ciency), were considered risk factors for 
the development of hyperinsulinemia, impaired glucose toler-
ance, and T2DM in pubertal and adult survivors, having TBI 
the strongest association (Neville et al 2006). Additionally, a 
waist to height ratio greater than 0.5 in prepubertal subjects Vascular Health and Risk Management 2008:4(4) 832
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Figure 1 Risk stratiﬁ  cation and treatment algorithm of childhood cancer survivors (Adapted from Kavey et al 2006).
Abbreviations: CVD, cardiovascular disease; M, male; F, female; BMI, body mass index; BP, blood pressure; FG, fasting glucose; HbA1C, glycated hemoglobin.Vascular Health and Risk Management 2008:4(4) 833
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may represent an early and simple clinical marker for the later 
development of metabolic disturbance (Neville et al 2006). To 
date, TBI as a preparative therapy for BMT is the key role in 
the genesis of IR, as stated by a large multicenter study that 
included survivors of both pediatric and adult BMT. The risk 
of developing T2DM was 3 times as likely to occur in BMT 
recipients as in a control group, and this risk was associated 
with TBI (Baker et al 2007). Nonetheless, the mechanisms 
underlying this still remain unclear. TBI has been shown to 
alter mitochondrial function in muscle, liver, and pancreas, 
resulting in the development of IR, and T2DM. Other mecha-
nisms related to the immunologic and inﬂ  ammatory effects 
of BMT may play a role in the development of such features. 
To date, the effect of TBI on the function of adipose tissue in 
secreting adipokines has not been studied yet (Neville et al 
2006; Baker et al 2007).
Interventions for cardiovascular 
risk reduction
Hormonal supplementation and primary or secondary preven-
tion of endothelial dysfunction are recommended to prevent 
MS and early atherosclerosis in long-term cancer survivors 
(Nuver et al 2002).
Primary prevention comprises prevention of hormonal 
deﬁ  ciencies and/or direct endothelial damage through more 
limited surgery, CT dose reduction, avoidance of unnecessary 
gonadotoxic CT, and the administration of alternative drugs.
Secondary prevention encompasses the following: 
supplementation of hormonal deﬁ  ciencies (thyroid, gonadal 
and/or GH); treatment of therapy-related endothelial dysfunc-
tion (IR, dyslipidemia, Mg+2 supplementation); and, ﬁ  nally, 
screening for the occurrence of MS, and treatment when 
appropriate (Nuver et al 2002).
Complementary interventional recommendations for car-
diovascular risk identiﬁ  cation and reduction were developed 
as a consensus by a writing group convened under the joint 
direction of the American Heart Association’s Expert Panel 
on Population and Prevention Science and the Council for 
Cardiovascular Disease in the Young, and an algorithm was 
developed outlining the risk factor evaluation, management, 
and therapeutic recommendations (Kavey et al 2006). See 
Figure 1 and Table 3.
Concluding remarks
The prevalence and pathogenesis of MS in long-term survi-
vors of cancer, the signiﬁ  cance of this syndrome, as well as 
Table 3 Treatment recommendations for childhood cancer survivors (Adapted from Kavey et al 2006)
Growth/diet
 •   Calculate BMI percentile for gender/heighta
 •   Age-appropriate reduced-calorie training for child and family, but adequate calories for growth
 •  Total  fat  30% of calories, saturated fat 10% of calories, cholesterol 300 mg/dL, avoid trans fats
Blood pressure
 •   BP measurement/interpretation for age/gender/heightb
 •  If  BP  = 90 to 95th percentile or 120 × 80 mmHg (3 separate occasions within 1 month): decrease calorie intake and increase exercise
 •    If initial BP 95th percentile (within 1 week) or 95th percentile during 6-months follow-up: pharmacological therapy per Fourth Task Force 
recommendationsc
Lipidsd
 •   If initial LDL-cholesterol 160mg/dL: diet with 30% fat, 7% saturated fat, cholesterol 200 mg/dL, avoidance of trans fats for 6 months
 •   Weight-loss management and exercise recommendations if overweight/obese
 •   If repeat LDL 160 mg/dL and child 10 yr: statin therapy with LDL goal of 130 mg/dL
 •  If  initial  TG  150 to 400 mg/dL: low carbohydrate and low-fat diet
 •  If  TG  700 to 1000 mg/dL, initial or follow-up: ﬁ  brate or niacin if 10 yr
Glucosee
 •   If fasting glucose = 100 to 126 mg/dL: reduced-calorie diet, increased activity over 6 months
 •   If repeat: insulin-sensitizing medication
 •  Casual  glucose  200 mg/dL or fasting glucose 126 mg/dL = diabetes mellitus = endocrine referral, maintain HbA1C 7%
Smoking
 •   Active antismoking counseling
Exercise
 •  Encourage  activity
Abbreviations: BMI, body mass index; BP, blood pressure; TG, triglycerides; HbA1C, glycated hemoglobin.
Notes: aNormal BMI values for age and sex: National Center for Health Statistics (NCHS) 2000; bNational High Blood Pressure Education Program Working Group on Hypertension 
Control in Children and Adolescents (1996); cNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents – Fourth 
report of the Task Force (2004); dAmerican Academy of Pediatrics [AAP] (1992); eAmerican Diabetes Association (ADA 2000).Vascular Health and Risk Management 2008:4(4) 834
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the relationship between MS and the development of CVD 
after cancer treatment, have to be clariﬁ  ed yet. However, if 
MS plays an important role in the development of CVD after 
cancer treatment, this syndrome might be a major target for 
intervention during follow-up of cancer survivors. The fol-
lowing observations must be considered:
1.  Oncologists who treat childhood cancer survivors, 
and particularly those who provide primary care to adult 
survivors, should be aware of the potential for long-term hor-
monal deﬁ  ciencies and adverse cardiovascular and diabetes 
risk proﬁ  les as a consequence of cancer treatment;
2. Some  speciﬁ  c cancer groups predisposing to MS 
traits, such as ALL, CNS tumors, lymphomas, sarcomas, 
testicular cancer, and following BMT, as well as RT or 
alkylating drugs regimens, must call for attention in order 
to early detect and treat any metabolic alteration or features 
of MS secondary to therapy;
3.  Attempts to prevent the problem of early AR in 
ALL patients are indicated in the interests of prevention 
of later obesity. These efforts might take the form of 
encouraging a more active lifestyle during the ﬁ  rst years 
of therapy;
4.  Hypothalamic obesity often results in devastating 
metabolic and psychosocial complications, requiring provi-
sion of dietary and behavioral modiﬁ  cations, encouragement 
of regular physical activity, psychological counseling, as well 
as antiobesity drugs;
5.  Alternative conditioning therapies for BMT can be 
considered without compromising survival, reducing the 
risk of metabolic abnormality. Early detection of abdominal 
adiposity and/or hormonal deﬁ  ciency may allow dietary, and 
lifestyle measures;
6.  Therapeutic lifestyle change, with emphasis on 
weight reduction, constitutes ﬁ  rst-line therapy. In patients 
in whom lifestyle changes fail to reverse metabolic risk 
factors, consideration should be given to treating speciﬁ  c 
abnormalities with drugs, according to current treatment 
guidelines;
7.  Overall, further research is still necessary to deﬁ  ne 
the epidemiology, risk factors, and mechanisms behind the 
development of metabolic disorders in survivors of pediatric 
cancers, particularly those involving endothelial and adipose 
tissue dysfunction.
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